Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

ABSTRACT:

Background

The rate of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) varies, and adjuvant therapy treatment for residual cancer remains a challenge. The aim of our study was to assess the added value of FoundationOne®CDx (F1CDx) testing in the non-metastatic TNBC in predicting responses to NACT and disease outcomes.

Methods

Ninety-three eligible patients with stage II-III TNBC were treated with NACT without immunotherapy. Response to NACT was evaluated postoperatively. Comprehensive genomic profiling with NGS-based molecular test F1CDx was performed on diagnostic biopsies (N = 93). Hierarchical clustering and logistic regression were applied for data analysis.

Results

Genomic profiling and data clust

SUBMITTER: Drobniene M 

PROVIDER: S-EPMC11891149 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature